Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis
NCT02148146 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2021-01-12
Summary
This is a clinical study designed to evaluate the safety and benefit of a fish oil based fat emulsion in the treatment of liver disease associated with prolonged use of intravenous nutrition.
Conditions
- Cholestasis
Interventions
- DRUG
-
Omegaven
Fish oil emulsion given 1g/kg/day as infusion
Sponsors & Collaborators
-
University of California, San Diego
lead OTHER
Principal Investigators
-
Sarah Lazar, MPH · UC San Diego Medical Center
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury
NCT01089426 ·Status: COMPLETED ·Phase: NA
-
Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis
NCT01173159 ·Status: COMPLETED ·Phase: NA
-
Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Associated Hepatic Injury
NCT01412359 ·Status: APPROVED_FOR_MARKETING
-
Compassionate Use of Omegaven in Children
NCT02370251 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children
NCT01194063 ·Status: COMPLETED ·Phase: PHASE3
-
Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease
NCT04697888 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Compassionate Use of Omegaven
NCT02778698 ·Status: APPROVED_FOR_MARKETING
-
Cholestasis Reversal: Efficacy of IV Fish Oil
NCT00910104 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis
NCT01601652 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease
NCT01739517 ·Status: UNKNOWN ·Phase: PHASE2
-
Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease
NCT00862446 ·Status: COMPLETED ·Phase: PHASE4
-
Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD
NCT02929303 ·Status: APPROVED_FOR_MARKETING
-
Cholestasis Prevention: Efficacy of IV Fish Oil
NCT00512629 ·Status: COMPLETED ·Phase: PHASE1
-
Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
NCT02534077 ·Status: APPROVED_FOR_MARKETING
-
A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease
NCT00969332 ·Status: TERMINATED ·Phase: PHASE2
-
Compassionate Use of IV Fish Oil for Parenteral Nutrition (PN) Liver Injury
NCT01425567 ·Status: APPROVED_FOR_MARKETING
-
Compassionate Use of Omegaven IV Fat Emulsion
NCT02477345 ·Status: NO_LONGER_AVAILABLE
-
Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)
NCT04807478 ·Status: WITHDRAWN
-
Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease
NCT01297933 ·Status: APPROVED_FOR_MARKETING
-
Compassionate Use of Omegaven IV Fat Emulsion
NCT00816348 ·Status: TERMINATED ·Phase: PHASE2
-
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
NCT06274788 ·Status: RECRUITING
-
Omegaven Protocol:Intermediate Size Patient Population
NCT03561194 ·Status: APPROVED_FOR_MARKETING
-
Minimization of IntraLipid Versus Omegaven
NCT01247012 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease
NCT01284049 ·Status: COMPLETED ·Phase: NA
-
Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children
NCT02925520 ·Status: NO_LONGER_AVAILABLE